MarketPulse

market performance

13 articles
The Motley FoolThe Motley Fool··Anthony Di Pizio

BlackRock's Tech ETF Soars 62% as AI Boom Eclipses Broader Market Gains

iShares Expanded Tech ETF ($IGM) returned 62% in 12 months, crushing S&P 500, Nasdaq-100, and Dow Jones through heavy semiconductor and AI exposure.
NFLXNVDAAMDMETAMSFT+6artificial intelligenceETF
The Motley FoolThe Motley Fool··Adria Cimino

Magnificent Seven Under Pressure: History Suggests Recovery Ahead for Tech Giants

Magnificent Seven tech stocks declined in Q1 2026 amid geopolitical tensions and AI investment concerns. Historical analysis suggests recovery likely, but diversification across other tech players is prudent.
NVDAMETAMSFTAMZNGOOG+6artificial intelligencelong-term investing
The Motley FoolThe Motley Fool··Johnny Rice

SpaceX's Historic $75B IPO Faces Valuation Scrutiny as Mega-IPOs Struggle

SpaceX targets historic $75B IPO at $2 trillion valuation, but recent mega-IPO analysis shows most underperformed markets, suggesting investor caution warranted.
NVDAMETASFTBYBBAAYGMvaluationIPO
The Motley FoolThe Motley Fool··Jennifer Saibil

Berkshire Hathaway's Trillion-Dollar Moat: Why $BRK.B Remains a Generational Wealth Play

Berkshire Hathaway's diversified portfolio of 190+ businesses and proven 60-year track record position it as a cornerstone generational wealth investment for disciplined long-term investors.
AXPAAPLBRK.ABRK.BKOlong-term investingClass B shares
BenzingaBenzinga··Surbhi Jain

SpaceX IPO Could Break Years of Post-2021 Value Destruction for IPO Investors

SpaceX's potential IPO faces investor skepticism from 2021 IPO failures, though the company's revenue and scale differ sharply from hyper-valued pre-revenue startups that collapsed.
RENTPATHGTLBBIRDBZFD+2IPOovervaluation
The Motley FoolThe Motley Fool··Leo Sun

Trump Media Stock Faces Uphill Battle Against Market Despite Crypto Pivot

$DJT has crashed from $70.90 debut to under $9. Truth Social stalls at 6.3M users while analysts warn stock unlikely to outperform market.
DJTDJTWWRUMRUMBWcryptocurrencyvaluation
The Motley FoolThe Motley Fool··Johnny Rice

Palantir's Perfect Execution Masks Valuation Risk as AI Competition Intensifies

Palantir trades at 87x price-to-sales, S&P 500's highest. Historical data shows only 21% of ultra-expensive stocks outperform annually.
MSFTPLTRvaluationenterprise AI
The Motley FoolThe Motley Fool··Johnny Rice

Palantir's Extreme Valuation Defies History as 80x Sales Multiple Raises Red Flags

Palantir trades at 80x sales—25x the S&P 500 average. History shows only 10% of companies at half this valuation beat the market over three years.
MSFTPLTRvaluationartificial intelligence
The Motley FoolThe Motley Fool··Neil Patel

Can Coca-Cola Justify Its Premium Valuation in a Mature Market?

Coca-Cola's fortress brand and dividend growth appeal, but elevated 25.6 P/E valuation in a mature, slow-growth industry suggests limited five-year return potential.
BRK.ABRK.BKOvaluationdividend stock
The Motley FoolThe Motley Fool··Keith Noonan

Palantir Stock Surges 547% in Five Years: Can It Sustain Momentum Amid Valuation Concerns?

Palantir surged 547% over five years but faces valuation scrutiny at 110x forward earnings. Strong Q4 growth and AI demand offer upside, though 26% recent pullback signals volatility ahead.
PLTRvaluationearnings growth
The Motley FoolThe Motley Fool··Keith Noonan

Can GTA VI Reverse Take-Two's Market Underperformance?

Take-Two's stock down 17% in 2026, lagging S&P 500 by significant margin. Grand Theft Auto VI's November launch expected to become major growth catalyst for company.
MSFTGOOGGOOGLSONYNTDOY+1AI toolsmarket performance
The Motley FoolThe Motley Fool··Trevor Jennewine

Wall Street Touts Mid and Small-Cap Funds Over S&P 500, But Skeptics Question the Thesis

State Street forecasts small and mid-cap index funds will outperform the S&P 500 over five years, but critics highlight a structural flaw: these funds sell winners graduating to larger indexes while holding losers.
IVOOVIOOS&P 500investment strategy
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals: Evaluating Path to Million-Dollar Returns

Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.
LLYVRTXbiotechcystic fibrosis